Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.31 |
| ▸ | BAD | Q92934 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18100991 | 0.84 | MAOA (0.37) | MAOADYRK1ASYKSLC22A12BAD | |
| SCHEMBL18103471 | 0.83 | MAOA (0.47) | MAOADYRK1ASYKPDE10ASLC22A12 | |
| SCHEMBL18100987 | 0.80 | MAOA (0.35) | MAOADYRK1ASYKPDE10A | |
| SCHEMBL15732195 | 0.80 | MAOA (0.45) | MAOADYRK1ASYKPDE10ASLC22A12 | |
| SCHEMBL18103474 | 0.80 | PDE10A (0.48) | MAOADYRK1APDE10A | |
| SCHEMBL18103477 | 0.80 | MAOA (0.47) | MAOADYRK1ASYKPDE10ASLC22A12 | |
| SCHEMBL18101001 | 0.78 | MAOA (0.37) | MAOADYRK1ASYKLMNABAD | |
| SCHEMBL18103475 | 0.77 | MAOA (0.45) | MAOADYRK1ASYKPDE10ASLC22A12 | |
| SCHEMBL24916401 | 0.76 | P2RX3 (0.42) | MAOADYRK1AKDM4EMAPTHPGD | |
| SCHEMBL18100993 | 0.76 | CYP11B1 (0.40) | MAOADYRK1ASYKPDE10ASLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9546156-B2 | N-bicyclic aryl,N'-pyrazolyl urea, thiourea, guanidine cyanoguanidine compounds as TrkA kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-20160280681-A1 | N-BICYCLIC ARYL,N'-PYRAZOLYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280681-A1 | N-BICYCLIC ARYL,N'-PYRAZOLYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | TK1, TNNI3K, CHUK | MAOA 1846/4885DYRK1A 544/4885SYK 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.